TABLE 2

Study-reported outcomes at follow-up

First author [ref.]Sample size nMean follow-up time monthsPH assessment methodMean sPAP after closure mmHgMean sPAP reduction mmHgPH prevalenceNYHA class III–IV
Veldtman [31]27NR (1–12)TTENR10#28.50
De Lezo [32]2821±14TTE34±1114#1000
Bruch [33]1310±4RHC49.9±17.8NR920
Balint [34]3931±15TTE/TEE44±1614#NR20
Yong [35]186Median (IQR) 15 (8–43)TTEMedian (IQR) 25.0 (24–49)Median (IQR) 5 (1–13)263.7
Yalonetsky [60]NRNR (1–12)TTENRNRNR
 Age 40–60 years26
 Age >60 years33.5
Altindag [37]4115±15TTE/TEENRNR385
Humenberger [38]28±19TTENR
 Age <40 years7526±55±80
 Age 40–60 years8430±68±90
 Age >60 years7443±149±144
Huang [39]¶,+723.4±9.7RHC/TTE21.0±3.816#13NR
Kefer [40]11260±34TTE31±117#5.48
Nakagawa [41]2719.1±11.3TEE27.2±7.3NRNR4
Mangiafico [42]NR (1–12)TTENR
 Age <40 years1028±2.87.1#0
 Age >40 years2028.4±6.512.8#0
Akagi [9]TTENRNR
 PHM group 1819±27 (3–83)40±90
 non-PHM group 21419±16 (4–61)38±100
Wang [43]17645.6±25.2TEENRNR71.7
Dalvi [44]439.5±8.5RHC55.7±9.212.8#NR0

Data are presented as mean±sd, mean (range) or %, unless otherwise stated. PH: pulmonary hypertension; sPAP: systolic pulmonary artery pressure; NYHA: New York Heart Association; PHM: pulmonary hypertension medication; NR: not reported; TTE: transthoracic echocardiography; RHC: right heart catheterisation; TEE: transoesophageal echocardiography. #: when mean sPAP reductions were not reported, we calculated (mean sPAP before closure (mmHg)) – (mean sPAP after closure (mmHg)); : study reported values for pulmonary arterial hypertension; +: study reported mean values as mPAP.